MONOPAR THERAPEUTICS (MNPR) Social Stream
MONOPAR THERAPEUTICS (MNPR) Price Targets From Analysts
Use the tables below to see what analysts covering MONOPAR THERAPEUTICS think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-15 | 4 | $49 | $9 | $32.666 | $0.44 | 7324.09% |
| 2022-02-16 | 3 | $49 | $9 | $27.25 | $0.44 | 6093.18% |
| 2022-03-25 | 4 | $49 | $9 | $27.25 | $0.44 | 6093.18% |
| 2022-05-16 | 4 | $49 | $8 | $26.5 | $0.44 | 5922.73% |
| 2022-08-11 | 4 | $40 | $8 | $18.75 | $0.44 | 4161.36% |
| 2022-10-05 | 4 | $18 | $5 | $9.666 | $0.44 | 2096.82% |
| 2022-11-11 | 4 | $40 | $5 | $17.25 | $0.44 | 3820.45% |
| 2023-01-09 | 4 | $40 | $6 | $18 | $0.44 | 3990.91% |
| 2023-03-24 | 5 | $40 | $6 | $19.2 | $0.44 | 4263.64% |
| 2023-03-28 | 5 | $18 | $6 | $12.8 | $0.44 | 2809.09% |
| 2023-05-11 | 5 | $17 | $3 | $10.25 | $0.44 | 2229.55% |
| 2023-05-15 | 5 | $17 | $2 | $9.25 | $0.44 | 2002.27% |
| 2023-08-10 | 4 | $17 | $15 | $16.333 | $0.44 | 3612.05% |
| 2023-11-10 | 3 | $15 | $2 | $8.5 | $0.44 | 1831.82% |
The Trend in the Analyst Price Target
Over the past 32 months, MNPR's average price target has gone down $23.67.
MNPR reports an average of 1,593.76% for its upside potential over the past 42 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-08-10 | 5 | 17.000 | 15 | 16.333 | 0.749 | 2080.64% |
| 2023-08-10 | 4 | 17.000 | 3 | 13.000 | 0.749 | 1635.65% |
| 2023-11-10 | 3 | 17.000 | 2 | 11.333 | 0.369 | 2971.27% |
| 2023-11-10 | 3 | 15.000 | 2 | 8.500 | 0.369 | 2203.52% |
| 2023-11-10 | 3 | 17.001 | 2 | 11.333 | 0.369 | 2971.27% |
MNPR Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.5 | 3 | 0 | 1 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
Over the past 15 months, MNPR's average broker recommendation rating worsened by 0.67.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MNPR as an investment opportunity.
- MNPR has a greater upside potential (average analyst target price relative to current price) than 1787.41% of all US stocks.
- MNPR has a lower variance in analysts' estimates than -1525.59% of all US stocks.
- In terms of how MONOPAR THERAPEUTICS fares relative to Healthcare stocks, note that its number of analysts covering the stock is greater than 329.38% of that group.
- In the context of Healthcare stocks, MONOPAR THERAPEUTICS's average analyst price target is greater than 504.93% of them.
In the Pharmaceutical Products industry, CNSP, TRVI, and MREO are the three stocks most similar to MONOPAR THERAPEUTICS regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for MNPR? Use POWR Ratings for clearer insight into price direction.